Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: Final results of a randomized European Organization for Research and Treatment of Cancer study

Journal of Clinical Oncology

Volumn 14, Issue 8, 1996, Pages 2266-2273

  Blijham, G ^a   Wagener, T ^a   Wils, J ^a   de Greve, J ^a   Buset, M ^a   Bleiberg, H ^a   Lacave, A ^a   Dalmark, M ^a   Selleslag, J ^a   Collette, L ^a   Sahmoud, T ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; METHOTREXATE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 9444270969     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.8.2266     Document Type: Article

References (37)

1. Bertino JR, Sawicki WL, Linquist CA, et al: Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res 37:327-328, 1977
2. Cadman E, Davis L, Heimer R: Enhanced 5-flourouracil nucleotide formation following methotrexate: Biochemical explanation for drug synergism. Science 205:1135-1137, 1979
3. Benz C, Schoenberg M, Choti M, et al: Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breat tumor cell lines. J Clin Invest 66:1162-1165, 1980
4. Kemeny NE, Ahmed T, Michaelson RA: Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: Attempt at correlation with tissue and blood levels of phosphoribonylphosphate. J Clin Oncol 2:311-315, 1984
5. Hermann R, Spehn J, Beyer JH, et al: Sequential methotrexate and 5-fluorouracil: Improved response rate in metastatic colorectal cancer. J Clin Oncol 2:591-594, 1984
6. Martin DS, Stolfi RL, Sawyer R, et al: Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy. Cancer Treat Rep 69:421-423, 1985
7. Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987
8. Shah A, MacDonald W, Goldie J: 5-FU infusion in advanced colorectal cancer: A comparison of three dose schedules. Cancer Treat Rep 69:739-742, 1985
9. Diaz-Rubio E, Aranda E, Martin M, et al: Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. Eur J Cancer 26:727-729, 1991
10. Ardalan B, Singh G, Silberman H: A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 6:1053-1058, 1988
11. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
12. Freedman LS: Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1:121-129, 1983
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
14. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
15. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-202, 1972
16. Piedbois P, Buyse M, Blijham GH, et al: Meta-analysis of randomized trials testing the biochemical modulation of 5-fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-analysis Project. J Clin Oncol 12:960-969, 1994
17. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial. J Clin Oncol 7:1437-1446, 1989
18. Hermann R, Knuth A, Kleeberg U, et al: Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer. Ann Oncol 3:539-543, 1992
19. Valone FH, Friedman MA, Wittlinger PS, et al: Treatment of patients with advanced colorectal carcinoma with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: A randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427-1436, 1989
20. Machiavelli M, Leone BA, Romero A, et al: Advanced colorectal carcinoma: A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone. Am J Oncol 14:211-217, 1991
21. Delfino C, Caccia G, Maniago O: Fluorouracil alone versus methotrexate + leucovorin + FU in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 11:521, 1992 (abstr)
22. Abad A, Garcia P, Gravalos C, et al: Phase III trial with methotrexate, 5-FU and high-dose leucovorin vs. 5-FU, leucovorin vs. 5-FU in advanced and metastatic colorectal cancer. Proc Am Soc Clin Oncol 11:459, 1992 (abstr)
23. Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
24. Poon MA, O'Connell MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991
25. Glimelius B: Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 4:235-240, 1993
26. Blijham GH, Wagener DJT, van Oosterom AT, et al: Phase II study of high dose 5-fluorouracil (FU) with oral leucovorin (LV) in advanced colorectal cancer. Ann Oncol 1:45, 1990 (abstr)
27. Vokes EE, Choi KE, Schilsky RL, et al: Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol 6:618-626, 1988
28. Danhauser LL, Heimer R, Cadman E: Lack of enhanced cytotoxicity of cultures L1210 cells using folinic acid in combination with sequential methotrexate and fluorouracil. Cancer Chemother Pharmacol 15:214-219, 1985
29. Mini E, Coronello M, Carotti S: Biochemical modulation of fluoropyrimidines by antifolates and folates in an in vitro model of human leukemia. J Chemother 2:17-27, 1990 (suppl 1)
30. Van der Wilt CL, Braakhuis JM, Pinedo HM, et al: Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: Potentiating or reversing effect? Int J Cancer 61:672-678, 1995
31. Romanini A, Li WW, Colofiore JR, et al: Leucovorin enhances cytotoxicity of trimetatrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF/CEM cells. J Natl Cancer Inst 84:1033-1038, 1992
32. Sobrero A, Romanini A, Russello O, et al: Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: Implications for the mechanism of their interaction. Eur J Clin Oncol 25:977-982, 1989
33. Kamen BA, Eibl B, Cashmore AR, et al: Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methol-6[(3,4,5-trimethoyanilino)quinazoline], a non-classical antifolate in methotrexate-resistant leukema cells in vitro. Biochem Pharmacol 33:1697-1699, 1984
34. Fry DW, Wasserman TH: Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates. Cancer Res 48:6986-6991, 1988
35. Conti JA, Kemeny N, Goker E, et al: A phase I trial of sequential trimetrexate (MTX), fluorouracil (FU) and high-dose leucovorin (LV) in previously treated patients (pts) with gastrointestinal (GI) carcinoma (Ca). Proc Am Soc Clin Oncol 12:567, 1993 (abstr)
36. Marsh JC, Bertino JR, Katz KH, et al: The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 9:371-380, 1991
37. Buroker TR, O'Connell MJ, Wienand HS, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1994